Expert Interview
Assessing the probability of success of INSM's inhaled liposomal amikacin (ALIS) phase 3 CONVERT trial to treat nontuberculous mycobacterium
Ticker(s): INSMA lung specialist who treats a significant number of resistant NTM patients who is very familiar with potential new agents in clinical trials.
Is the phase 3 CONVERT trial well designed?
Added By: efk_crWhat is the probability that ALIS will succeed considering the requirement of 3 negative sputum cultures?
Added By: efk_crWhat is the expected placebo rate in the CONVERT trial given the requirement for 3 negative sputum cultures.
Added By: efk_crALIS has multiple serious side effects. What is an acceptable side effect profile for the drug considering the severity of the disease.
Added By: efk_crPlease review the phase 2 data and explain how it would inform us on the likelihood of success in the CONVERT trial.
Added By: efk_crDiscuss the market size of resistant NTM patients who are not cured by the standard of care.
Added By: efk_crAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
